ETF Holdings Breakdown of CNTA

CNTA institutional holdings

The adjusted close for CNTA on 2025-11-12 was 26.70

The following institutional investment holdings of CNTA have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share	Comment
2025-11-12	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	61,711	USD 1,647,684	26.70
2025-11-12	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	61,711 0.3%	USD 1,647,684 15.8%	26.70
Total =		123,422	USD 3,295,368

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with CNTA

Centessa Pharmaceuticals (NASDAQ:CNTA) Coverage Initiated at Oppenheimer

Oppenheimer began coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTA – Free Report) in a research report sent to investors on Friday morning. The firm issued an outperform rating and a $40.00 target price on the stock. CNTA has been the topic of several other research reports. Chardan Capital reaffirmed a “buy” rating and set a […] - 2025-09-01 03:02:48

Centessa Pharmaceuticals (NASDAQ:CNTA) Earns “Buy” Rating from Chardan Capital

Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at Chardan Capital in a report issued on Tuesday,Benzinga reports. They currently have a $30.00 price target on the stock. Chardan Capital’s price objective would suggest a potential upside of 75.03% from the stock’s current price. A number of […] - 2025-08-14 03:14:57

Analysts Set Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Price Target at $28.10

Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Get Free Report) have earned an average rating of “Buy” from the eleven analysts that are covering the company, Marketbeat.com reports. Eleven equities research analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have issued a report on […] - 2025-08-13 03:04:43

XTX Topco Ltd Increases Position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA)

XTX Topco Ltd raised its holdings in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Free Report) by 81.0% in the first quarter, Holdings Channel.com reports. The firm owned 41,057 shares of the company’s stock after purchasing an additional 18,377 shares during the period. XTX Topco Ltd’s holdings in Centessa Pharmaceuticals were worth $590,000 […] - 2025-08-06 05:20:57

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) CEO Sells $875,600.00 in Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Get Free Report) CEO Saurabh Saha sold 55,000 shares of the stock in a transaction on Monday, July 21st. The shares were sold at an average price of $15.92, for a total value of $875,600.00. Following the completion of the sale, the chief executive officer owned 221,017 shares […] - 2025-07-23 05:50:50

Centessa Pharmaceuticals (NASDAQ:CNTA) Coverage Initiated at Truist Financial

Investment analysts at Truist Financial initiated coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) in a research report issued to clients and investors on Monday, Marketbeat.com reports. The brokerage set a “buy” rating and a $30.00 price target on the stock. Truist Financial’s target price indicates a potential upside of 85.53% from […] - 2025-07-23 05:10:48

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Average Rating of “Buy” from Brokerages

Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Get Free Report) have received an average recommendation of “Buy” from the ten ratings firms that are covering the company, Marketbeat Ratings reports. Ten equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have updated […] - 2025-07-16 02:49:05

Centessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Down 3.8% Following Insider Selling

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Get Free Report) shares fell 3.8% during trading on Thursday following insider selling activity. The stock traded as low as $12.95 and last traded at $12.93. 65,287 shares were traded during mid-day trading, a decline of 91% from the average session volume of 726,424 shares. The stock had […] - 2025-06-27 02:17:08

Saurabh Saha Sells 55,000 Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Get Free Report) CEO Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $12.63, for a total value of $694,650.00. Following the completion of the transaction, the chief executive officer now owns […] - 2025-06-23 05:25:00

Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stake Lowered by Two Sigma Investments LP

Two Sigma Investments LP reduced its stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA – Free Report) by 63.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 37,900 shares of the company’s stock after selling 66,008 shares during the period. […] - 2025-06-09 04:56:44

Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives $27.00 Average PT from Brokerages

Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) has been given a consensus rating of “Buy” by the ten research firms that are currently covering the stock, Marketbeat reports. Ten research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokers that have updated their coverage on the stock […] - 2025-05-30 03:06:54

Centessa Pharmaceuticals (NASDAQ:CNTA) Coverage Initiated at Needham & Company LLC

Stock analysts at Needham & Company LLC assumed coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) in a note issued to investors on Wednesday, MarketBeat reports. The brokerage set a “buy” rating and a $35.00 price target on the stock. Needham & Company LLC’s price objective indicates a potential upside of 167.79% […] - 2025-05-30 02:21:02

Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap Up After Insider Buying Activity

Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) gapped up before the market opened on Tuesday following insider buying activity. The stock had previously closed at $12.26, but opened at $12.74. Centessa Pharmaceuticals shares last traded at $12.97, with a volume of 107,299 shares trading hands. Specifically, Director Arjun Goyal acquired 417,646 shares of the […] - 2025-05-22 02:32:56

Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock Holdings Increased by Barclays PLC

Barclays PLC grew its position in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA – Free Report) by 1,414.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,302 shares of the company’s stock after buying an additional 4,952 shares during the period. […] - 2025-05-15 04:31:09

Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives $27.71 Consensus PT from Analysts

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) have received a consensus rating of “Buy” from the eight analysts that are currently covering the stock, MarketBeat reports. Eight analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have issued a report on the stock in […] - 2025-05-05 02:34:53

Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives $27.71 Average Price Target from Brokerages

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) have been given a consensus rating of “Buy” by the eight brokerages that are currently covering the stock, MarketBeat reports. Eight investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have issued a report on […] - 2025-04-10 03:07:13

Centessa Pharmaceuticals (NASDAQ:CNTA) Now Covered by Analysts at Piper Sandler

Stock analysts at Piper Sandler initiated coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) in a research report issued to clients and investors on Monday, MarketBeat Ratings reports. The brokerage set an “overweight” rating and a $38.00 price target on the stock. Piper Sandler’s target price indicates a potential upside of 187.23% […] - 2025-04-02 03:12:49

Guggenheim Reaffirms Buy Rating for Centessa Pharmaceuticals (NASDAQ:CNTA)

Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Guggenheim in a research report issued on Wednesday,Benzinga reports. They presently have a $28.00 price target on the stock. Guggenheim’s target price suggests a potential upside of 92.97% from the stock’s previous close. Several other brokerages have […] - 2025-03-28 05:02:42

Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells $917,950.00 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) CEO Saurabh Saha sold 55,000 shares of the business’s stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $16.69, for a total transaction of $917,950.00. Following the transaction, the chief executive officer now owns 276,017 shares of the company’s […] - 2025-03-24 06:04:57

Analysts Set Centessa Pharmaceuticals plc (NASDAQ:CNTA) Target Price at $25.83

Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) has earned an average recommendation of “Buy” from the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have issued a report on the stock […] - 2025-02-19 04:12:50

Back to Listing

Disclaimer